Mushrooms and Brain Inflammation: Neuroprotective Effects

Mushrooms & Inflammation

49 weeks

The longest mushroom brain health clinical trial tested Erinacine A-enriched Lion's Mane for 49 weeks in mild Alzheimer's patients and found significant improvement in MMSE cognitive scores versus placebo; the only double-blind RCT showing a mushroom compound improving Alzheimer's cognitive outcomes.

Li IC et al., Front Aging Neurosci, 2020

J Neuroinflammation

Ganoderma polysaccharides suppress IL-1β, IL-6, and iNOS in BV2 microglia (Cai et al., 2017); published in the field's primary journal

7 molecular targets

cordycepin inhibits neuroinflammation by simultaneously targeting 7 distinct signaling molecules (Govindula et al., 2021)

4 MAPK pathways

mixed mushroom formula suppressed JNK, ERK, p38, and IκB simultaneously in BV2 microglial cells (Lee et al., Cells, 2025)

Li IC et al., Front Aging Neurosci, 2020

View as image ↗

In a 49-week double-blind placebo-controlled trial, patients with mild Alzheimer's disease who received Erinacine A-enriched Lion's Mane mycelium showed significantly better scores on the Mini-Mental State Examination than those who received placebo.^[3] This is the longest and most rigorous clinical study of any mushroom compound for a neurological condition, yet it is largely absent from consumer content about medicinal mushrooms and brain health.

That gap extends across the broader neuroinflammation research. Ganoderma polysaccharides suppress microglia-mediated neuroinflammation in a study published in the Journal of Neuroinflammation, the primary specialty journal for this research area.^[1] Cordyceps' active compound cordycepin targets 7 distinct neuroinflammatory signaling molecules.^[4] A 2025 study of a mixed mushroom formula suppressed four parallel neuroinflammatory pathways simultaneously in brain immune cells.^[5]

None of these findings appear in mainstream content about mushrooms and brain inflammation. This article covers the multi-species evidence, the mechanisms, and what the data actually supports.

For the broader framework on mushroom anti-inflammatory mechanisms, see How Mushrooms Fight Inflammation: NF-κB, COX-2, and Beyond.

Why Brain Inflammation Is Different from Systemic Inflammation

The brain has its own dedicated immune cells called microglia. Unlike macrophages in the body, microglia are embedded throughout brain tissue and cannot easily be replaced if they dysfunction. Their job is surveillance: detecting pathogens, clearing debris, and responding to tissue damage.

Under conditions of acute infection or injury, microglia activate into what researchers call the M1 state: pro-inflammatory, releasing cytokines like IL-1β, IL-6, and TNF-α, and producing nitric oxide via the enzyme iNOS. This is a protective response. The problem arises when microglia stay in the M1 state chronically, which is a feature of Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Chronically activated M1 microglia damage the neurons they were meant to protect.

The alternative state, M2, is anti-inflammatory and regenerative: microglia in the M2 state produce TGF-β and other signals that promote neuronal survival and tissue repair. Shifting microglia from M1 to M2, or preventing excessive M1 activation in the first place, is the core mechanism by which several mushroom compounds appear to offer neuroprotection.

Lion's Mane: From Microglia to a Clinical Trial

Lion's Mane (Hericium erinaceus) has the strongest evidence chain of any mushroom for neuroinflammation, running from cell culture to animal models to a clinical trial.

Kushairi et al. (2019) tested Lion's Mane ethanolic extract directly against LPS-activated BV2 microglia, the standard cell model for neuroinflammation research.^[7] Lion's Mane significantly reduced nitric oxide production in the activated microglia. The same extract also protected HT22 hippocampal neurons from hydrogen peroxide-induced oxidative damage. That is two relevant cell types responding to the same extract: immune cells quieted and neurons protected.

Tsai-Teng et al. (2016) moved to a transgenic mouse model of Alzheimer's disease, administering Erinacine A-enriched Lion's Mane mycelium orally for 30 days.^[2] Erinacine A is a diterpenoid compound found in Lion's Mane mycelium (not the fruiting body) with direct NGF-stimulating properties. In the transgenic mice, the treatment reduced cerebral amyloid-beta plaque burden (one of the hallmarks of Alzheimer's pathology), reduced neuroinflammatory markers, and improved behavioral performance. The amyloid reduction was not a trivial effect; it suggests that the neuroinflammatory suppression translated to reduced pathological protein accumulation.

Li et al. (2020) then tested this in human patients.^[3] The trial enrolled patients with mild Alzheimer's disease in a 49-week double-blind, placebo-controlled design. The active treatment was Erinacine A-enriched Lion's Mane mycelium at a dose delivering 5 mg/g of erinacine A. The primary outcome was MMSE (Mini-Mental State Examination) score, the standard clinical assessment of cognitive function. The treatment group showed significantly better MMSE scores than placebo at the 49-week endpoint.

This trial is described as a "pilot" study, indicating a smaller sample size than a definitive Phase III trial, and replication in larger trials would be needed before clinical conclusions can be drawn. But it is the only double-blind RCT showing cognitive improvement from a mushroom compound in Alzheimer's patients with significant statistical results, and it is based on 49 weeks of treatment; a timeframe long enough to capture genuine cognitive trajectory changes.

For a deeper look at the specific compounds driving these effects, see Hericenones and Erinacines: Lion's Mane's Brain-Boosting Compounds.

Ganoderma: The Journal of Neuroinflammation Paper

Cai et al. (2017) published a study specifically examining Ganoderma lucidum polysaccharides (GLP) and microglia in the Journal of Neuroinflammation; the primary peer-reviewed authority for this research area.^[1] The journal selection matters: work published there is evaluated by specialists in neuroinflammation science.

The study activated BV2 microglia using two different stimuli: LPS (a bacterial toxin used to trigger M1 inflammation) and amyloid-beta (the Alzheimer's-relevant protein). GLP inhibited the pro-inflammatory response to both. The cytokines IL-1β and IL-6 were reduced. The enzyme iNOS (which produces the neurotoxic molecule nitric oxide) was reduced. At the same time, TGF-β; an anti-inflammatory and tissue-repair cytokine associated with M2 polarization; was elevated.

Beyond cytokine effects, Cai et al. also measured microglial behavior: phagocytosis (the cell's ability to engulf and clear debris) and migration. GLP modulated both, suggesting Ganoderma polysaccharides affect not just what microglia produce but how they physically operate in brain tissue. This is a mechanistic layer that goes beyond simple cytokine suppression.

Ren et al. (2019) validated the neuroprotective effects of Ganoderma in a Parkinson's disease animal model.^[6] MPTP is a neurotoxin that destroys dopaminergic neurons in the substantia nigra, producing a Parkinson's-like syndrome in mice. Ganoderma extract significantly protected dopaminergic neurons from MPTP-induced loss by regulating mitochondrial function, reducing oxidative stress, and modulating autophagy and apoptosis pathways. Parkinson's disease is driven by a combination of neuroinflammation and mitochondrial dysfunction; Ganoderma appears to address both in this model.

Cordyceps: Seven Molecular Targets in One Compound

Cordycepin (3'-deoxyadenosine), the primary bioactive compound in Cordyceps species, has been studied extensively for its anti-neuroinflammatory effects. Govindula et al. (2021) synthesized this research into a review that explicitly mapped cordycepin's neuroinflammatory targets.^[4]

The seven molecular targets cordycepin addresses in neuroinflammation:

1. Adenosine A2 receptor; cordycepin modulates adenosine signaling, which has direct effects on microglial activation state
2. NF-κB; the master inflammatory transcription factor; cordycepin inhibits its activation
3. NLRP3 inflammasome; a protein complex that triggers the release of IL-1β; cordycepin suppresses its assembly
4. IL-1β; the primary pro-inflammatory cytokine produced by activated microglia; directly reduced
5. iNOS; the enzyme producing neurotoxic nitric oxide; inhibited
6. COX-2; cyclooxygenase-2, the inflammation enzyme; suppressed
7. HMGB1; a late-phase inflammatory mediator that drives sustained neuroinflammation; reduced

Addressing seven distinct signaling molecules across three different pathway levels (receptor, transcription factor, and downstream effectors) is a degree of mechanistic breadth that single-target pharmaceutical anti-inflammatory agents typically do not match. Govindula et al. proposed that this multi-target profile makes cordycepin particularly effective in chronic neuroinflammatory contexts where multiple pathways are simultaneously dysregulated.

The 2025 Multi-Species Synergy Data

Lee et al. (2025) tested a mixed mushroom mycelia extract (a multi-species formula designated GMK) against LPS-induced neuroinflammation in BV2 microglia and neurotoxicity in PC12 neurons.^[5]

The anti-neuroinflammatory mechanism was mapped to four parallel MAPK (mitogen-activated protein kinase) pathways: JNK, ERK, p38, and the upstream regulator IκB. These are distinct signaling cascades that converge on inflammatory gene expression. The mixed mushroom formula inhibited phosphorylation (activation) of all four simultaneously, reducing downstream production of NO, TNF-α, and IL-6. The same extract also protected PC12 neuronal cells from neurotoxicity.

The simultaneous targeting of four pathways is mechanistically significant. Each pathway can independently drive neuroinflammation; inhibiting one while the others remain active produces incomplete suppression. A formula that addresses all four simultaneously suggests either that multiple compounds in the mixture work on different pathways, or that certain shared compounds have unusually broad-spectrum activity.

This 2025 data is the most current preclinical evidence in the neuroinflammation-mushroom literature and has not yet appeared in any consumer content.

For the general cytokine modulation mechanisms relevant across mushroom species, see How Mushrooms Modulate Inflammatory Cytokines. For the Alzheimer's-specific cross-species comparison, see Cross-Species Mushroom Research in Alzheimer's: Lion's Mane, Reishi, and Cordyceps.

Evidence Levels: Where Each Species Stands

The research across these species differs substantially in evidence quality. Understanding what stage each finding is at is necessary for accurate expectations.

Lion's Mane has the strongest translational evidence chain: cell model data (Kushairi 2019), transgenic animal model data (Tsai-Teng 2016), and a human RCT with significant cognitive outcomes (Li 2020). The human trial is a pilot study with limitations in sample size, but it exists and showed significant results.

Ganoderma has high-quality cell model data (Cai 2017, J Neuroinflammation) and validated animal model data for Parkinson's (Ren 2019, 2022). No human RCT for neurological conditions exists.

Cordyceps has mechanistic review-level evidence establishing the multi-target profile (Govindula 2021). The reviews draw on multiple cell and animal studies. No human RCT for brain inflammation exists.

Mixed formulas have the 2025 cell model data (Lee 2025). No animal or human data yet for the specific combination.

For all species: no mushroom supplement is approved for treating Alzheimer's disease, Parkinson's disease, or any neurological condition. The Li 2020 Alzheimer's pilot trial is not sufficient evidence for clinical guidance. The evidence is promising and justifies continued research; it does not justify medical claims.

The Bottom Line

Three mushroom species have distinct, mechanistically detailed evidence for brain anti-inflammatory effects. Lion's Mane has the most complete evidence chain, from BV2 microglia cell data (Kushairi 2019) to Alzheimer's transgenic mouse model (Tsai-Teng 2016) to a 49-week double-blind RCT showing MMSE improvement in mild Alzheimer's patients (Li 2020). Ganoderma polysaccharides suppress microglial M1 activation in research published in the Journal of Neuroinflammation (Cai 2017) and protect dopaminergic neurons in a Parkinson's model (Ren 2019). Cordycepin targets 7 distinct neuroinflammatory molecules (Govindula 2021). A 2025 mixed mushroom formula suppressed four MAPK pathways simultaneously in BV2 cells (Lee 2025). Nearly all evidence outside of the Li 2020 pilot RCT is preclinical.

Frequently Asked Questions

What mushrooms are neuroprotective?

Three mushroom species have the strongest preclinical evidence for neuroprotection: Lion's Mane (Hericium erinaceus), Ganoderma lucidum (reishi), and Cordyceps species. Lion's Mane has an Erinacine A-based mechanism confirmed in cell models, Alzheimer's transgenic mice, and a 49-week human pilot RCT (Li et al., 2020). Ganoderma polysaccharides suppress microglia-mediated neuroinflammation in cell models (Cai et al., J Neuroinflammation, 2017) and protect dopaminergic neurons in a Parkinson's mouse model. Cordycepin targets seven distinct neuroinflammatory molecules. A 2025 mixed mushroom formula showed synergistic effects across four MAPK pathways in brain immune cells.

Can mushrooms protect the brain from inflammation?

In preclinical research, yes. Multiple mushroom compounds suppress the pro-inflammatory activation of microglia, the brain's resident immune cells, and protect neurons from inflammatory damage. The mechanisms include Ganoderma polysaccharides shifting microglia from M1 (pro-inflammatory) to M2 (anti-inflammatory) states (Cai et al., 2017), Lion's Mane reducing nitric oxide production in LPS-activated microglia (Kushairi et al., 2019), and cordycepin blocking seven distinct neuroinflammatory pathways (Govindula et al., 2021). In humans, the Li 2020 pilot RCT of Erinacine A-enriched Lion's Mane showed cognitive score improvement in mild Alzheimer's patients over 49 weeks, though this is a single pilot trial requiring replication.

Which medicinal mushrooms help with brain health?

By evidence strength: (1) Lion's Mane has a human clinical trial (Li 2020, 49 weeks, significant MMSE improvement in mild Alzheimer's), animal model data, and cell model data for specific neuroinflammatory mechanisms. (2) Ganoderma has cell model data published in the Journal of Neuroinflammation and Parkinson's animal model neuroprotection data. (3) Cordyceps has the most comprehensively mapped anti-neuroinflammatory mechanism via cordycepin. Mixed mushroom formulas have 2025 cell data showing multi-pathway synergy. All evidence except the Li 2020 trial is preclinical.

Do mushrooms reduce neuroinflammation?

Preclinical evidence consistently shows that several mushroom compounds reduce neuroinflammation in BV2 microglial cell models. Ganoderma polysaccharides reduce IL-1β, IL-6, and iNOS while increasing TGF-β in LPS- and amyloid-beta-activated microglia (Cai et al., 2017). Lion's Mane extract reduces nitric oxide in LPS-activated BV2 microglia and protects hippocampal neurons from oxidative damage (Kushairi et al., 2019). Cordycepin targets seven molecules in the neuroinflammatory cascade (Govindula et al., 2021). In the one human trial available (Li 2020, mild Alzheimer's), 49 weeks of Erinacine A-enriched Lion's Mane produced significantly better cognitive scores than placebo.

What are the best anti-inflammatory mushrooms for brain health?

Based on the available research: Lion's Mane has the deepest and most translatable evidence, with the only human clinical trial data (Li 2020 Alzheimer's RCT) and specific mechanisms traced to the erinacine A compound in the mycelium. Ganoderma is the best-studied for microglial modulation, with the Cai 2017 Journal of Neuroinflammation paper providing the most mechanistically detailed cell data in this research space. Cordyceps has the broadest mechanistic profile per compound (7 neuroinflammatory targets for cordycepin). Mixed formulas targeting multiple pathways simultaneously represent the most recent direction of the research. The compounds in all three species are complementary rather than redundant in their neuroinflammatory mechanisms.

Sources & References

1. 1RTHM-00462·Cai, Qing et al. (2017). “Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response..” Journal of neuroinflammation.Study breakdown →PubMed →↩
2. 2RTHM-00452·Tsai-Teng, Tzeng et al. (2016). “Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice..” Journal of biomedical science.Study breakdown →PubMed →↩
3. 3RTHM-00631·Li, I-Chen et al. (2020). “Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study..” Frontiers in aging neuroscience.Study breakdown →PubMed →↩
4. 4RTHM-01359·Govindula, Anusha et al. (2021). “Molecular mechanisms of cordycepin emphasizing its potential against neuroinflammation: An update..” European journal of pharmacology.Study breakdown →PubMed →↩
5. 5RTHM-02125·Lee, Sang-Seop et al. (2025). “Neuroprotective Effect of Mixed Mushroom Mycelia Extract on Neurotoxicity and Neuroinflammation via Regulation of ROS-Induced Oxidative Stress in PC12 and BV2 Cells..” Cells.Study breakdown →PubMed →↩
6. 6RTHM-01118·Ren, Zhi-Li et al. (2019). “Ganoderma lucidum extract ameliorates MPTP-induced parkinsonism and protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis..” Acta pharmacologica Sinica.Study breakdown →PubMed →↩
7. 7RTHM-01078·Kushairi, Naufal et al. (2019). “Lion's Mane Mushroom, Hericium erinaceus (Bull.: Fr.) Pers. Suppresses H2O2-Induced Oxidative Damage and LPS-Induced Inflammation in HT22 Hippocampal Neurons and BV2 Microglia..” Antioxidants (Basel.Study breakdown →PubMed →↩